LGND News and Press, Ligand Pharmaceuticals Incorporated From 09/10/20

The acquired technologies continue to position Ligand’s OmniAb as a best-in-class platform for antibody discovery Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb ® te...

There are a number of reasons why you might be interested in the future sales/revenue growth of a company. For instance, in order to perform a discounted cash flow analysis of a stock, it's one of the essential inputs. Or perhaps, you believe that the higher a company's projected sales growth,...

Merger activity increased last week with four new deals announced and two deals completed. M&A activity continues to pick up pace as we come close to the end of the third quarter. We had been tracking two of the four new deals announced last week in our "Deals in the Works" table before ...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at an upcoming investor conference. Management will deliver a company presentation for the H.C. Wainwright 22 nd annual global investment virtual conference on Monday, September 14 ...

IMVT-1401 is a novel anti-FcRn OmniAb-derived antibody delivered by subcutaneous injection Registration-enabling Phase 3 trial expected to initiate in the first half of 2021 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, Inc. (NASDAQ: IMV...

KYPROLIS is an Amgen product that utilizes Captisol ® in its formulation Approval based on the CANDOR and EQUULEUS Studies Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug A...

Merger activity increased significantly last week with eight new deals announced and one deal terminated. This is the highest number of deals announced in a single week this year but most of these deals were relatively small compared to the multi-billion-dollar deals we saw in the week prior...

Ligand Pharmaceuticals ( LGND ) is a company with an interesting business model, one which I have provided coverage on at various occasions in the past. The last update on the company and the investment thesis dates March 2019 as I concluded that uncertainty prevails. This uncertainty ca...

Ligand reports planned acquisition of Pfenex Ligand Pharmaceuticals Inc. ( LGND ) announced that it has inked a definitive agreement with Pfenex Inc. ( PFNX ) for acquiring the latter. The companies expect the transaction to be closed in the fourth quarter of 2020, subject to required re...

Ligand Pharmaceuticals (NASDAQ: LGND ) has agreed to acquire Pfenex (NYSEMKT: PFNX ) at $12/share, equivalent to $438M in equity value, representing a 57% premium to Pfenex’s last close price of $7.66 on August 10. More news on: Ligand Pharmaceuticals Incorporated, Pfenex Inc....